Multidisciplinary

Top Medical News
Product Highlight - Amnoz
6 hours ago
Amlodipine 5 mg and 10 mg tab
Product Highlight - Roxatin
6 hours ago
Rosuvastatin 10 mg and 20 mg FC tab
Product Highlight - Cruzor
6 hours ago
Irbesartan 300 mg FC tab
MEFIB bests MAST, FAST for fibrosis detection in NAFLD
17 hours ago
Magnetic resonance elastography (MRE) plus FIB-4 (MEFIB) outperforms both magnetic resonance imaging [MRI]-aspartate aminotransferase (MAST) and FibroScan-AST (FAST) in detecting stage ≥2 fibrosis and at-risk nonalcoholic steatohepatitis (NASH), reveals a study.
Do aortic annular size, valve type affect outcomes after TAVI?
Stephen Padilla, 18 hours ago
Aortic annular size does not appear to have a major impact on valve haemodynamics, prosthesis-patient match (PPM), and mortality following transcatheter aortic valve implantation (TAVI), according to the results of a Singapore study.
Intermittent fasting may not be healthy after all
Elvira Manzano, 18 hours ago
Currently in vogue, intermittent fasting (IF) – which switches between periods of eating and fasting – may not be as beneficial as many have thought.
Lung fibrosis extent on quantified CT predicts survival in IPF
19 hours ago
The extent of fibrotic abnormality on baseline computed tomography (CT), quantified using data-driven texture analysis (DTA), is predictive of outcomes in patients with idiopathic pulmonary fibrosis (IPF), regardless of pulmonary function, suggests a study.
Special Reports
Product Highlight - Amnoz
30 Nov 2022
Amlodipine 5 mg and 10 mg tab
Product Highlight - Cruzor
30 Nov 2022
Irbesartan 300 mg FC tab
Product Highlight - Roxatin
30 Nov 2022
Rosuvastatin 10 mg and 20 mg FC tab
When dengue fever becomes severe
01 Nov 2022
Dengue has been around for more than a century from the first reported outbreak in 1902,1 with experts advising healthcare professionals (HCPs) from time to time to alert HCPs to the threats of dengue. This is because the dengue virus has been evolving and can cause severe illness especially among vulnerable patients regardless of age. In this fourth interview of a series focused on dengue, Dr Shanthi Ratnam, Consultant Physician and Intensivist, elaborated on the risks, impact and management of dengue, and advocated dengue as a public health priority.
Pregabalin mainstay of treatment in painful diabetic neuropathy
01 Nov 2022
At the recent Novugen Expert Forum, held in Penang, Dr Khaw Chong Hui discussed the prevalence of painful diabetic neuropathy (PDN), role of pregabalin in the treatment of PDN, its place in treatment recommendations of major international pain guidelines and its proven safety and efficacy.
Molecular Pathogenesis and Current Treatment Landscape In MPN, With A Focus On PV
01 Nov 2022
The recent Northern Haematology Update, held in Penang, saw Dr Christopher Ng, Dr Tan Sui Keat and Dr Carol Goh present on various aspects of myeloproliferative neoplasms (MPN)and its management. Dr Christopher Ng, a haematology trainee at Hospital Sultanah Bahiyah, Kedah, discussed the role of mutations as drivers of disease, with a focus on polycythaemiavera (PV) and essential thrombocythaemia (ET).
Role of Primary Care in the Diagnosis and Management of Multiple Myeloma
01 Nov 2022
Early detection is vital to the successful treatment of multiple myeloma (MM), a type of bone marrow cancer characterised by abnormal expansion of malignant clonal plasma cells in the bone marrow.
Conference Reports
CT angiography may increase potential recipients of EVT for acute ischaemic stroke
Roshini Claire Anthony, 27 Nov 2022

Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.

No CV benefits with cooler dialysate
Elvira Manzano, 27 Nov 2022
The use of a cooler dialysate during maintenance haemodialysis does not offer cardiovascular (CV) benefits to patients in the MyTEMP trial.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Roshini Claire Anthony, 25 Nov 2022

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Letermovir as good as valganciclovir for CMV prophylaxis
Elaine Soliven, 25 Nov 2022
The novel antiviral letermovir is as good as the current standard of care valganciclovir in preventing cytomegalovirus (CMV) infection in post-kidney transplant patients, but with less toxicity, according to a phase III trial presented at IDWeek 2022.
Post-surgery emergence delirium in kids has no long-term impact
Roshini Claire Anthony, 23 Nov 2022

The use of general anaesthesia (GA) in children undergoing elective surgeries does not lead to long-term deterioration in behavioural outcomes, according to a study presented at Anesthesiology 2022.

TB rates elevated after ART initiation in PLHIV
Roshini Claire Anthony, 21 Nov 2022

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

Low use of CVD prevention strategies in people with HIV
Roshini Claire Anthony, 18 Nov 2022

There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.